StreetInsider.com News Articles

Contamination Protection Solution Highlights Covalon’s Presence at the Association for Vascular Access 2026 Annual Scientific Meeting

Mon, 28 Sep 2026 07:00:00 -0400

Meeting to be held October 2 - 4, 2026, at the Gaylord Texan Resort & Convention Center in Grapevine, Texas, with pre-meeting workshops on October 1

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its participation at the Association for Vascular Access (AVA) Annual Scientific Meeting in Grapevine, Texas, from October 2 to 4, 2026, with pre-meeting workshops on October 1. Attendees will have the opportunity to explore Covalon’s innovative vascular access and infection prevention solutions and learn why leading hospitals in the United

Contamination Protection Solution Highlights Covalon’s Presence at the Association for Vascular Access 2026 Annual Scientific Meeting

Mon, 28 Sep 2026 07:00:00 -0400

Meeting to be held October 2 - 4, 2026, at the Gaylord Texan Resort & Convention Center in Grapevine, Texas, with pre-meeting workshops on October 1

Contamination Protection Solution Highlights Covalon’s Presence at the Association for Vascular Access 2026 Annual Scientific Meeting

Mon, 28 Sep 2026 07:00:00 -0400

Meeting to be held October 2 - 4, 2026, at the Gaylord Texan Resort & Convention Center in Grapevine, Texas, with pre-meeting workshops on October 1

Contamination Protection Solution Highlights Covalon’s Presence at the Association for Vascular Access 2026 Annual Scientific Meeting

Mon, 28 Sep 2026 07:00:00 -0400

Meeting to be held October 2 - 4, 2026, at the Gaylord Texan Resort & Convention Center in Grapevine, Texas, with pre-meeting workshops on October 1

Covalon Reports Encouraging Findings From Real World Evidence Analysis Comparing Collagen Dressings

Thu, 24 Sep 2026 07:00:00 -0400

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced encouraging findings from a retrospective real world evidence analysis of collagen advanced wound care dressings conducted with Intellicure LLC, a highly respected wound care data analytics firm.

The analysis used de-identified records from the US Wound Registry and a Bayesian ordinal model to estimate the probability of reaching substantial granulation coverage at four, eight, and twelve weeks in patients with diabetic foot ulcers and venous leg ulcers that presented with no granulation tissue at baseline. Wounds were

Covalon Reports Encouraging Findings From Real World Evidence Analysis Comparing Collagen Dressings

Thu, 24 Sep 2026 07:00:00 -0400

Covalon Reports Encouraging Findings From Real World Evidence Analysis Comparing Collagen Dressings

Thu, 24 Sep 2026 07:00:00 -0400

Covalon Reports Encouraging Findings From Real World Evidence Analysis Comparing Collagen Dressings

Thu, 24 Sep 2026 07:00:00 -0400

Covalon to Present at the 2026 Annual Smallcap Discoveries Conference After Reporting Revenue Growth of 20% and Gross Margin of 67%

Tue, 22 Sep 2026 07:00:00 -0400

Presentation at 10:00 a.m. PT / 1:00 p.m. ET on Monday, September 28, 2026

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company today announced that it will present at the 2026 Annual Smallcap Discoveries Conference, being held at the JW Marriott Parq in Vancouver, British Columbia, Canada on September 28 and 29, 2026.

Brent Ashton, Covalon’s Chief Executive Officer, will present on Monday, September 28, 2026, at 10:00 a.m. PT (1:00 p.m. ET) and will also participate in one-on-one meetings with investors during the conference.

The presentation follows

Covalon to Present at the 2026 Annual Smallcap Discoveries Conference After Reporting Revenue Growth of 20% and Gross Margin of 67%

Tue, 22 Sep 2026 07:00:00 -0400

Presentation at 10:00 a.m. PT / 1:00 p.m. ET on Monday, September 28, 2026

The presentation follows

Covalon to Present at the 2026 Annual Smallcap Discoveries Conference After Reporting Revenue Growth of 20% and Gross Margin of 67%

Tue, 22 Sep 2026 07:00:00 -0400

Presentation at 10:00 a.m. PT / 1:00 p.m. ET on Monday, September 28, 2026

The presentation follows

Covalon to Present at the 2026 Annual Smallcap Discoveries Conference After Reporting Revenue Growth of 20% and Gross Margin of 67%

Tue, 22 Sep 2026 07:00:00 -0400

Presentation at 10:00 a.m. PT / 1:00 p.m. ET on Monday, September 28, 2026

The presentation follows

Covalon Reports Fiscal 2026 Third Quarter Results

Thu, 27 Aug 2026 07:00:00 -0400

Revenue rises 20% year-over-year to over $10.0 million
Gross margin expands to 67.2% from 46.5% in the prior year
Earnings Per Share of $0.10, more than double the previous quarter
Contamination Protection revenue increased 68% year-over-year and 34% over the previous quarter

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 third quarter results for the period ended June 30, 2026. Full financial statements and management’s discussion and analysis are available on the Company’s profile at www.sedarplus.ca.